Pharma

Your Article Summary

See Latest Articles

Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
Gilead, 11/03/09

Gilead Sciences, Inc., in collaboration with GlaxoSmithKline, announced plans for an international, event–driven clinical trial to study combination therapy versus monotherapy in a first–line treatment setting for pulmonary arterial hypertension. The study, AMBITION, will evaluate first–line combination use with ambrisentan, an endothelin receptor antagonist and tadalafil, a PDE5 inhibitor, in patients with PAH. Ambrisentan is approved under the tradename Letairis as a once–daily treatment for PAH in patients with WHO functional class II or III symptoms to improve exercise capacity and delay clinical worsening.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Results from two Phase II trials add to understanding of ticagrelor and how it works in the body
AstraZeneca, 11/19/09

Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
Genzyme, 11/19/09

 See all of Drug Trials

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09

Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
Genzyme, 11/19/09

Par pharmaceutical receives final approval to market generic ultram er
Par Pharmaceutical, 11/17/09

 See all of Drug/Product Approvals

Today in Medical Devices/Products...keeping you current

Receive free subspecialty "5-minute updates" via email

Wearable Sensors to Detect Agents, Disease
HealthDataManagement, 11/23/09

Medtronic Chairman and CEO Bill Hawkins Comments on U.S. Senates Revised Medical Device Industry Fee Proposal
Medtronic, 11/20/09

Sanofi-aventis and Medicines for Malaria Venture to launch the largest ever study of an antimalarial drug
Sanofi-aventis, 11/20/09

 See all of Medical Devices/Products

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Canadian Vendor to Buy Rival
HealthDataManagement, 11/23/09

I.T. App Focuses on Skeletal Diseases
HealthDataManagement, 11/23/09

CCHIT Seeks Comments on Criteria
HealthDataManagement, 11/23/09

 See all of Research & Development